Laure Deyme

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Topics

Epidermal Growth Factor Receptor

Placebo Controlled

Endoplasmic Reticulum Stress

Top Venues

CPT: pharmacometrics & systems pharmacology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Javier Cortes, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Sylvaine Cartot-Cotton, Maya Stefanova-Urena, Laure Deyme, Jihane Aouni, Bernard Sebastien, Aditya Bardia
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Marc Cerou, Hoai-Thu Thai, Laure Deyme, Sophie Fliscounakis-Huynh, Emmanuelle Comets, Patrick Cohen, Sylvaine Cartot-Cotton, Christine Veyrat-Follet
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Marc Cerou, Hoai-Thu Thai, Laure Deyme, Sophie Fliscounakis-Huynh, Emmanuelle Comets, Patrick Cohen, Sylvaine Cartot-Cotton, Christine Veyrat-Follet
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Marc Cerou, Hoai-Thu Thai, Laure Deyme, Sophie Fliscounakis-Huynh, Emmanuelle Comets, Patrick Cohen, Sylvaine Cartot-Cotton, Christine Veyrat-Follet
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials. CPT: pharmacometrics & systems pharmacology (2024)
Javier Cortes, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Sylvaine Cartot-Cotton, Maya Stefanova-Urena, Laure Deyme, Jihane Aouni, Bernard Sebastien, Aditya Bardia
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (22) (2024)
Marc Cerou, Hoai-Thu Thai, Laure Deyme, Sophie Fliscounakis-Huynh, Emmanuelle Comets, Patrick Cohen, Sylvaine Cartot-Cotton, Christine Veyrat-Follet
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Laure Deyme, Dominique Barbolosi, Litaty Céphanoée Mbatchi, Nicole Tubiana-Mathieu, Marc Ychou, Alexandre Evrard, Florence Gattacceca
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Cancer chemotherapy and pharmacology 88 (2) (2021)
Laure Deyme, Dominique Barbolosi, Florence Gattacceca
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. Cancer chemotherapy and pharmacology 83 (1) (2018)